Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exogen Avoids Lengthy MCAC Process In HCFA Coverage Review

This article was originally published in The Gray Sheet

Executive Summary

The Health Care Financing Administration plans to develop a national Medicare coverage decision for Exogen's Sonic Accelerated Fracture Healing System (SAFHS) without bringing the issue before the Medicare Coverage Advisory Committee, agency staffers report.

You may also be interested in...



Exogen Registry Data "Minimally Acceptable" For SAFHS Medicare Coverage

Exogen's registry data and several well-controlled foreign studies were sufficient for the Health Care Financing Administration to approve the firm's request for national Medicare coverage for the Sonic Accelerated Fracture Healing System (SAFHS).

Exogen Registry Data "Minimally Acceptable" For SAFHS Medicare Coverage

Exogen's registry data and several well-controlled foreign studies were sufficient for the Health Care Financing Administration to approve the firm's request for national Medicare coverage for the Sonic Accelerated Fracture Healing System (SAFHS).

MCAC Panel Finds Evidence Insufficient To Evaluate Pelvic Stim, Biofeedback

Members of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee were asked not to address Medicare coverage in their April 12-13 discussions of two established urinary incontinence therapies - a limitation that turned out to be a determining factor for some in the voting process.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel